EGFR-Mutant NSCLC in Community Settings: Practical Guidance on First-Line Intensification Without Upfront TP53 Status

In this episode, Dr. Yu and Dr. Puri offer practical guidance for community oncologists treating newly diagnosed EGFR-mutant metastatic non–small cell lung cancer (NSCLC), where access to rapid TP53 reporting and multidisciplinary supportive care may be limited. Dr. Puri's core advice: when EGFR status is confirmed, discuss combination therapy upfront, before TP53 results are back. If the patient starts on combination and TP53 mutation is identified later, she generally does not switch between combination regimens. For a patient already on osimertinib monotherapy, typically because performance status, comorbidities, or adverse-event (AE) concerns ruled out combination therapy, a later TP53 finding prompts a fresh conversation. Dr. Puri tells the patient that the co-mutation predicts a poorer outcome with single-agent therapy and offers the option to add chemotherapy based on the TOP data. If they remain unsuitable for or unwilling to accept combination therapy, monotherapy continues. Dr. Yu agrees with this framework, supporting an opt-out default that does not depend on having TP53 results in hand at treatment initiation.

In the next episode, “Unanswered Questions and the Role of ctDNA Dynamics,” Dr. Puri and Dr. Yu close the program by discussing what TOP did not answer and where the field is heading.